Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Hepalatide (L47) in Type 2 Diabetes Mellitus
NCT04662164Phase 2Withdrawn
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Dec 2025
- Modality
- Modified Peptides, Native Peptides
01
Overview
A Phase 2 trial of hepalatide in type 2 diabetes mellitus (T2DM), sponsored by Shanghai Hepu Pharmaceutical. Planned start Dec 2025; status: withdrawn.
02
Drugs
hepalatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04662164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662164.